Torvalipin Tablet 10 mg

Nchi: Singapoo

Lugha: Kiingereza

Chanzo: HSA (Health Sciences Authority)

Viambatanisho vya kazi:

Atorvastatin calcium 10.36mg corresponding to atorvastatin

Inapatikana kutoka:

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

ATC kanuni:

C10AA05

Kipimo:

10 mg

Dawa fomu:

TABLET, FILM COATED

Tungo:

Atorvastatin calcium 10.36mg corresponding to atorvastatin 10 mg

Njia ya uendeshaji:

ORAL

Dawa ya aina:

Prescription Only

Viwandani na:

Actavis Ltd

Idhini hali ya:

ACTIVE

Idhini ya tarehe:

2012-06-22

Tabia za bidhaa

1. NAME OF THE MEDICINAL PRODUCT
Torvalipin tablets 10 mg
Torvalipin tablets 20 mg
Torvalipin tablets 40 mg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 10mg of Torvalipin film-coated tablet contains atorvastatin
calcium corresponding
to 10mg of atorvastatin base.
Each 20mg of Torvalipin film-coated tablet contains atorvastatin
calcium corresponding
to 20mg of atorvastatin base.
Each 40mg of Torvalipin film-coated tablet contains atorvastatin
calcium corresponding
to 40mg of atorvastatin base.
For a full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Film-coated tablet.
10 mg: White, oval, biconvex film-coated tablets marked with “10”
on one side and “A”
on the other”.
20 mg: White, oval, biconvex film-coated tablets marked with “20”
on one side and “A”
on the other”.
40 mg: White, oval, biconvex film-coated tablets marked with “40”
on one side and “A”
on the other”.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
_Hypercholesterolaemia _
Torvalipin is indicated as an adjunct to diet for reduction of
elevated total
cholesterol, LDLcholesterol, apolipoprotein B, or triglycerides in
patients with primary
hypercholesterolaemia including heterozygous familial
hypercholesterolaemia or
combined (mixed) hyperlipidaemia (such as Frederickson’s types IIa
and IIb), when
satisfactory results have not been obtained by a special diet or
measures other than
medication.
Torvalipin is also indicated to reduce totalcholesterol and
LDL-cholesterol in patients
with homozygous familial hypercholesterolaemia as an adjunct to other
lipid-lowering
treatments (e.g. LDL apheresis) or if such treatments are unavailable.
_Prevention of Cardiovascular Disease _
Torvalipin is indicated to reduce the risk of myocardial infarction in
adult hypertensive
patients without clinically evident coronary heart disease, but with
at least three
additional risk factors for coronary heart disease such as age ≥ 55
years, male
sex, smoking, left ventricular hypertrophy, other specified
abnormalities on